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ULTRA-SMALL RNAS AS TOLL-LIKE
RECEPTOR-3 ANTAGONISTS

sequence-speci?c double-stranded RNA of 22 nucleotides or
shorter length Which binds to but does not activate the activity
of a TLR3.

Which claims priority under 35 USC §119 to US. Provi

In yet another aspect, the present invention relates to a
method for increasing the speci?city of a desired siRNA
target knockdoWn. The method comprises administering an

sional Application No. 61/030,487, ?led Feb. 21, 2008, the
entire disclosure of Which is herein expressly incorporated by

amount of a target siRNA su?icient to knockdoWn a target
gene and an amount of a double stranded RNA of 22 nucle

reference.

otides or less Which prevents the target siRNA from activating

The instant application contains a Sequence Listing Which
has been submitted via EFS-Web and is hereby incorporated

TLR3.
In still another aspect the present invention relates to a

This application is a national stage of PCT International

Application No. PCT/US2009/001106, ?led Feb. 20, 2009,

method for screening for a compound that antagonizes TLR3.
The method comprises contacting TLR3 or binding fragment
thereof With a test compound, and determining if a complex is
formed betWeen TLR3 or binding fragment thereof and the
test compound.
Other systems, methods, features and advantages of the

by reference in its entirety.
FIELD OF THE INVENTION

The present invention relates to the ability of ultra-small
RNAs to act as toll-like receptor-3 (TLR3) antagonists.
BACKGROUND

present invention Will be or become apparent to one With skill
20

systems, methods, features and advantages be included

The macula is the part of the retina Which is responsible for
central vision. Age-related macular degeneration is a chronic

Within this description, be Within the scope of the present

invention, and be protected by the accompanying claims.

eye disease that occurs When tissue in the macula deteriorates.

Macular degeneration affects central vision, but not periph
eral vision. Macular degeneration is the leading cause of
severe vision loss in people age 60 and older.
There are tWo forms of age-related macular degeneration:
dry and Wet. Dry macular degeneration is the most common
type of macular degeneration and occurs When cells of the

25

FIG. 1 illustrates the effect of poly (I:C) and poly (dI:dC)
30

FIG. 3 illustrates the effect of intravitreous administration

35

FIG. 4 shoWs the effect of intravitreous administration of

poly (I:C), poly (I:CIZU) and poly (dI:dC) on choroidal
neovasculariZation (CNV) in Tlr3"/+ and Tlr3_/_ mice.
40

FIG. 5 illustrates the effect of 9 to 23 nucleotide versions of
siRNA-Luc on CNV in Wild-type mice.
FIG. 6 shoWs the effect of 21-nt siRNA-Luc and 21-nt
dsDNA on the ability of 23-nt siRNA-Luc to suppress CNV in

Wild-type mice.
FIG. 7 illustrates ability of 2'O-methyl-21-nt siRNA-Luc

its. This is Where neW blood vessel groWth, or neovascular

cholesterol, 2'O-methyl-18-nt siRNA-Luc-cholesterol, and

iZation, occurs. Central vision can become distorted or lost
45

2'O-methyl-15-nt siRNA-Luc-cholesterol to rescue human

retinal pigmented epithelial cells from poly (I:C) induced

cytotoxicity.

the cases of age-related macular degeneration, but it accounts
for about 90 percent of the cases of legal blindness.
SUMMARY OF THE INVENTION

poly (I:C) on survival of retinal pigmented epithelial cells
from Wild-type and Tlr3_/_ mice.
of poly (I:C) on activated caspase-3 expression in retinal
pigmented epithelial cells from Wild-type and Tlr3"/+ mice.

retina. The drusen deposits are debris associated With com

entirely in a short period of time, sometimes Within days. Wet
macular degeneration is responsible for about 10 percent of

BRIEF DESCRIPTION OF THE DRAWINGS

on survival of human retinal pigmented epithelial cells.
FIG. 2 shoWs the effect of intravitreous administration of

macula sloWly begin to break doWn. YelloW deposits called
“drusen” form under the retina betWeen the retinal pigmented
epithelium (RPE) and Bruch’s membrane, Which supports the
promised cell metabolism in the RPE. Eventually there is a
deterioration of the macular regions associated With the
drusen deposits resulting in a loss of central vision.
Wet macular degeneration occurs When abnormal blood
vessels groW behind the macula. These vessels are fragile and
can leak ?uid and blood, Which result in scarring of the
macula and raise the potential for rapid, severe damage.
Bruch’s membrane breaks doWn, usually near drusen depos

in the art upon examination of the folloWing draWings and
detailed description. It is intended that all such additional

FIG. 8 shoWs immunohistochemistry using a monoclonal
50

anti-long dsRNAAb (J 2), Which reveals blue reaction product
in drusen (arrow), RPE, Bruch’s membrane and choriocapil
laris (asterisk, collectively) in a donor eye of an 84-year-old

patient With GA (a). Isotype control Ab revealed no speci?c
immunostaining in another region of the same eye (b). J2 did

In one aspect the present invention relates to a method of

treating or preventing macular degeneration. The method
comprises exposing a retinal or choroidal cell to a toll-like
receptor 3 (TLR3)-antagonistic effective amount of a double
stranded RNA of 22 nucleotides or shorter length Whichbinds
to but does not activate the activity of a TLR3.
In yet another aspect, the present invention relates to a

not stain the retina or choroid of a 78-year-old patient Without
55

FIG. 9 provides color fundus photographs shoWing that
intravitreous administration of Ampligen® (poly I:C12U; 2
pg), a double stranded RNA that speci?cally activates TLR3,

method of treating or preventing a disease or disorder asso

ciated With activation of TLR3. The method comprises expos
ing a subject in need thereof to a toll-like receptor 3 (TLR3)
antagonistic effective amount of a double-stranded RNA of
22 nucleotides or shorter length Which binds to but does not
activate the activity of a TLR3
In another aspect, the present invention relates to a com

position for the treatment or prevention of macular degenera
tion. The composition comprises a sequence-nonspeci?c or

AMD (c). Images are representative of 5-7 eyes per group.

60

induces retinal degeneration (arroWs) in Wild-type C57Bl/6J
mice (left panel) but not in TLR3 —/— mice (right panel). The
photographs Were taken 10 days after Ampligen® injection.
FIG. 10 provides color fundus photographs shoWing that
intravitreous administration of Ampligen® (poly I:C12U; 2
pg) in Wild-type mice does not cause retinal degeneration

65

When neutraliZing anti-TLR3 antibody (eBioscience; 12 pg)
is co-administered (left panel). It Was further shoWn that

isotype control antibody (IgG; Jackson Immunoresearch; 12

US 8,481,508 B2
3

4

pg) does not block the effects of Ampligen® (right panel).
The photographs Were taken 10 days after Ampligen® and

example, administration of antagonists of TLR3 inhibits the
geographic atrophy of macular degeneration such as the geo

antibody injection.

graphic atrophy of dry macular degeneration. Geographic

FIG. 11 provides color fundus photographs showing that
retinal degeneration induced by intravitreous administration

atrophy includes choroidal atrophy and retinal atrophy. Com
positions and methods for blocking the activity of TLR3 for

of Ampligen® (poly I:Cl2U; 2 pg) in Wild-type mice (left

the treatment and/ or prevention of macular degeneration are

panel) does not occur When blunt end double stranded 5-nt

provided.

dsRNA conjugated to cholesterol (chol) is co-administered

Any double-stranded RNA of 22 nucleotides or shorter
length Which binds to but does not activate TLR3 may be used

(right panel). The photographs Were taken 10 days afterAmp
ligen® and 5-nt-dsRNA injection.
FIG. 12 provides color fundus photographs shoWing that
retinal degeneration induced by intravitreous administration
of Ampligen® (poly I:Cl2U; 2 pg) in Wild-type mice (left

in the present invention. Natural agonists for TLR3 include
viral double-stranded RNA. Any natural agonist of TLR3 can
be converted to an antagonist by shortening the length to 22
nucleotides or less. Such shortened double-stranded RNAs

panel) does not occur When blunt end double stranded 7-nt

dsRNA (4 pg) conjugated to cholesterol (chol) is co-admin
istered (right panel). The photographs Were taken 10 days
after Ampligen® and 7-nt-dsRNA injection.
FIG. 13 provides color fundus photographs shoWing that
retinal degeneration induced by intravitreous administration
of Ampligen® (poly I:Cl2U; 2 pg) in Wild-type mice (left

bind to but do not activate TLR3 activity. Preferably, the
length of the double-stranded RNA is 5-22 nucleotides. Pref
erably, the length of the double-stranded RNA is 5-15 nucle
otides. More preferably, the length is 7-11 nucleotides.
In addition, other ligands can also be used to antagonize
20

panel) does not occur When cholesterol (chol)-conjugated
double stranded l6-nt-dsRNA (8 pg), Which contains 14 base
pairs on each strand With 2-nt overhangs on each strand, is

co-administered (right panel). The photographs Were taken
10 days after Ampligen® and l6-nt-dsRNA injection.
FIG. 14 provides transmission electron micrographs shoW
ing that intravitreous administration of Ampligen® (poly

I:Cl2U; 2 pg) in Wild-type mice (left panels) results in pho
toreceptor outer segment (POS) damage (red arroWheads; top
left) and degeneration of retinal pigmented epithelial (RPE)

stranded RNA having a length of 22 nucleotides or less. The
double stranded RNA can be an siRNA, or any other double
25

30

35

the length includes those RNAs Which contain some single

sense strand or antisense strand or both, such as overlaps of

dT residues. The length of all single stranded and double
stranded regions are added to determine the overall length of

shoWing that a-Wave amplitude is attenuated by intravitreous
administration of Ampligen® (poly I:Cl2U; 2 pg) in Wild
type mice, as compared to phosphate buffered saline (PBS).
Co-administration of 16 nt-dsRNA-chol (8 pg) rescued the
ERG a-Wave attenuation.

stranded RNA, as long as the length is 22 nucleotides or less.
While the constructs containing the double-stranded RNA are
effective When made With either blunt ends or With overhangs,
if overhangs are used the nucleotides comprising the over
hangs are considered part of 22 or less total nucleotides.
Thus, a double stranded RNA of 22 nucleotides or shorter
stranded portion as long as a majority of the molecule has a
double stranded RNA structure. Such double stranded RNAs
include RNAs Which have a double stranded central portion
and having 3' overlaps of l, 2, 3 or more nucleotides on the

cells in Wild-type mice. Co-administration of l6-nt-dsRNA
chol (8 pg) preserves the anatomical architecture of the POS
and RPE. The images Were taken 2 Weeks after drug admin
istration.

FIG. 15 provides scotopic electroretinograms (ERG)

TLR3 activity. Such ligands include sequence-speci?c (or
targeted) and sequence-nonspeci?c (or non-targeted) double

40

FIG. 16 shoWs that double stranded RNA requires a cell

permeating entity for intemaliZation by mammalian cells.

the double stranded RNA. For example, a double stranded
RNA having a 16 nucleotide central double stranded RNA
structure and 3' overlaps of dTdT on both the sense and
antisense strands Would have an overall length of 20 nucle
otides. Double stranded RNAs are also contemplated Which

Mouse endothelial cell cultures Were exposed to ?uorescein

have one or more internal nucleotides Which do not have a

conjugated dsRNA (Fl-dsRNA) folloWed by time-lapse con

base pair. Double stranded RNAs also include those RNAs

focal microscopy (left panel, Nomarski, right panel, green

45

With no single stranded regions at all, such as a blunt end
double stranded RNA of 22 nucleotides or less.
The siRNAs for use in the present invention are designed
according to standard methods in the ?eld of RNA interfer
ence. Introduction of siRNAs into cells may be by transfec

50

tion With expression vectors, by transfection With synthetic

channel). When Fl-dsRNA Was conjugated With cholesterol
(Fl-dsRNA Chol), a cell-permeant entity, there Was robust
LEC internalization.
DETAILED DESCRIPTION

dsRNA, or by any other appropriate method. Transfection
With expression vectors is preferred. Alternatively, the cell

Toll-like receptors (TLRs) are type I transmembrane pro

teins involved in innate immunity by recogniZing microbial

exterior can be exposed to a composition containing the siR
NAs of the present invention.

conserved structures. Toll-like receptors can help activate the

adaptive immune response, thereby linking innate and
acquired immune responses. Ten TLRs (named TLRl to
TLRlO) have been identi?ed in humans, With each TLR being
speci?c for a different microbial-associated molecular pat
tern. The present inventor has surprisingly found that double
stranded RNAs of 22 nucleotides (nt) or shorter lengthbind to
but do not activate toll-like receptor-3 (TLR3) and, among
other things, can inhibit the geographic atrophy of macular

55

lentiviral vectors. The expression vector includes a sequence
Which codes for a portion of a target gene or any other
sequence Whether speci?c for a particular gene or a nonsense
60

ing geographic atrophy of macular degeneration such as the

geographic atrophy of dry macular degeneration. For

sequence. The gene sequence is designed such that, upon
transcription in the transfected host, the RNA sequence forms
a hairpin structure due to the presence of self-complementary

degeneration.
In one aspect, methods and compositions are provided for
the treatment or prevention of macular degeneration, includ

The expression vectors Which can be used to deliver siRNA

according to the invention include retroviral, adenoviral and

bases. Processing Within the cell removes the loop resulting in
formation of a siRNA duplex. The double stranded RNA
65

sequence should be less than 23 nucleotides; preferably the
dsRNA sequence is 15-22 nucleotides in length; more pref
erably the dsRNA sequence is 21 nucleotides in length, or 18

